Evidence map›Paper›PMID 39030513›Full record

ArticleBMC biotechnology2024

Validation of a rapid collagenase activity detection technique based on fluorescent quenched gelatin with synovial fluid samples.

Miguel de la Fuente, Diego Delgado, Maider Beitia, Gabriel Barreda-Gómez, Arantxa Acera, Mikel Sanchez, Elena Vecino

Abstract readValidation Study
In one paragraph

Article in BMC biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Miguel de la FuenteDepartment of Cell Biology and Histology, Experimental Ophthalmo-Biology Group (GOBE, www.ehu.eus/gobe), University of the Basque Country UPV/EHU, Leioa, 48940, Spain.
Diego DelgadoAdvanced Biological Therapy Unit, Hospital Vithas Vitoria, Vitoria-Gasteiz, 01008, Spain.
Maider BeitiaAdvanced Biological Therapy Unit, Hospital Vithas Vitoria, Vitoria-Gasteiz, 01008, Spain.
Gabriel Barreda-GómezResearch and Development Division, IMG Pharma Biotech, Zamudio, Bizkaia, Spain.
Arantxa AceraDepartment of Cell Biology and Histology, Experimental Ophthalmo-Biology Group (GOBE, www.ehu.eus/gobe), University of the Basque Country UPV/EHU, Leioa, 48940, Spain.
Mikel SanchezAdvanced Biological Therapy Unit, Hospital Vithas Vitoria, Vitoria-Gasteiz, 01008, Spain.
Elena VecinoDepartment of Cell Biology and Histology, Experimental Ophthalmo-Biology Group (GOBE, www.ehu.eus/gobe), University of the Basque Country UPV/EHU, Leioa, 48940, Spain. elena.vecino@ehu.eus.

Funding

Basque Government (BIKAINTEK) 48-AF-W2-2019-00006ELKARTEK KK-2019/00086FISS FISS-21-RD21/0002/0041MINECO-Retos PID2019-111139RB-I00University of the Basque Country (PIFIND19/02) 201900016247
6 · The paper itself

Abstract

backgroundMeasuring collagenase activity is crucial in the field of joint health and disease management. Collagenases, enzymes responsible for collagen degradation, play a vital role in maintaining the balance between collagen synthesis and breakdown in joints. Dysregulation of collagenase activity leads to joint tissue degradation and diseases such as rheumatoid arthritis and osteoarthritis. The development of methods to measure collagenase activity is essential for diagnosis, disease severity assessment, treatment monitoring, and identification of therapeutic targets.

resultsThis study aimed to validate a rapid collagenase activity detection technique using synovial fluid samples. Antibody microarray analysis was initially performed to quantify the levels of matrix metalloproteinase-9 (MMP-9), a major collagenase in joints. Subsequently, the developed gelatin-based test utilizing fluorescence measurement was used to determine collagenase activity. There was a significant correlation between the presence of MMP-9 and collagenase activity. In addition, Lower Limit of Detection and Upper Limit of Detection can be preliminary estimated as 8 ng/mL and 48 ng/mL respectively.

conclusionsThe developed technique offers a potential point-of-care assessment of collagenase activity, providing real-time information for clinicians and researchers. By accurately quantifying collagenase activity, healthcare professionals can optimize patient care, improve treatment outcomes, and contribute to the understanding and management of joint-related disorders. Further research and validation are necessary to establish the full potential of this rapid collagenase activity detection method in clinical practice.

Indexed as

GelatinMatrix Metalloproteinase 9Synovial FluidCollagenasesFluorescent DyesHumansCollagenasesFluorescent DyesGelatinMatrix Metalloproteinase 9MMP9 protein, humanBiomarkerCollagenase activityGelatinIn vitro diagnosisMMP-9Point of care

Identifiers

PMID39030513
PMCPMC11264812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.